Fifty to 80 years ago, the synthetic estrogen DES was commonly prescribed to women who were at risk for miscarriage and premature births. Now dozens of their daughters who have developed breast cancer…
A European Medicines Agency committee recommended that Roche Holding's Perjeta, or pertuzumab, in combination with Herceptin -More- …
Roche Holding's Perjeta, or pertuzumab, significantly extended survival of women with HER2-positive breast cancer during a la -More- …
MISSISSAUGA, ON, Dec. 10, 2012 /CNW/ - Roche today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta (pertuzumab), Herceptin (trastuzu…
